Evaluation of Adoptive Tumor-Infiltrating Lymphocyte Therapy Combined with Chemoimmunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

The primary objective of the study is to evaluate the efficacy of **adoptive TIL therapy** in combination with chemoimmunotherapy in patients with advanced **non-small cell lung cancer (NSCLC)**. This is clinically relevant as NSCLC is a prevalent form of lung cancer, and exploring new therapeutic combinations could potentially improve patient outcomes. The study aims to assess whether this combination can enhance treatment efficacy compared to existing standard therapies.

The clinical trial focuses on **respiratory tract diseases** and includes both male and female participants. The study population comprises individuals from two age categories, specifically adults and adolescents. Participants are not part of a vulnerable population. The sponsor did not provide information regarding the total number of participants. The selection process for the trial population and any relevant lifestyle considerations, such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of adoptive TIL therapy in combination with chemoimmunotherapy for patients with advanced **non-small cell lung cancer (NSCLC)**. This study is structured as a Phase 1 trial, which is typically focused on assessing the safety, tolerability, and optimal dosing of the investigational treatment. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from June 4, 2023, to June 4, 2027, allowing for comprehensive data collection and analysis over a four-year period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining the suitability of participants for the trial based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled and randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health, treatment response, and any adverse events. These visits are essential for ensuring participant safety and for collecting data on the investigational therapy's effects. The trial will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed on their involvement in the study.

The expected length of participant involvement in the trial is contingent upon the individual treatment regimen and response, but it generally aligns with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are meticulously crafted to uphold the highest standards of scientific rigor and ethical conduct, ensuring that the data generated will contribute valuable insights into the treatment of advanced NSCLC.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified. Furthermore, there is no information on the product's authorization status or its pharmaceutical form.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. The documentation does not include information on any additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial's protocol lacks comprehensive data on the treatments involved.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is June 4, 2023, with an anticipated end date of June 4, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the intervention's effect on the disease or condition under investigation. The trial will likely employ standardized methods for measuring and analyzing efficacy, which may include validated scales, laboratory tests, or other objective measures. The schedule for these assessments is not specified, but they are typically conducted at various timepoints throughout the trial to monitor changes and trends. The data collected will be analyzed to determine the intervention's impact on the disease, providing insights into its potential therapeutic benefits.